Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, an FDA document related to the oral treatment ...
The U.S. Food and Drug Administration said Eli Lilly is required to conduct post-marketing trials to gauge risks for ...
April 14 (Reuters) - The U.S. Food and Drug Administration has asked Eli Lilly for more data on liver injury linked to its ...
With a second oral GLP-1 for obesity now approved in the U.S., analysts have set to work parsing the blockbuster potential of ...
Obesity threatens the health of men and women in different ways: the former are more likely to suffer from the accumulation of visceral fat and liver disorders, the latter from inflammation and high ...
New findings reveal that obesity significantly impaired the quality and longevity of antibody responses to a Pseudomonas aeruginosa vaccine in a mouse model. The impaired antibody production was due ...
The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday approved Novo Nordisk's (NVO) new single-dose 7.2mg ...
New research being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (May 12–15), reveals ...
MedPage Today on MSN
Proposed Obesity Criteria Could Delay Care, Top Society Warns
Revised diagnostic framework may limit access to early treatment, widen healthcare dispari ...
Kailera Therapeutics is advancing a pipeline of obesity drugs, led by the GLP-1/GIP dual agonist ribupatide, which the ...
Guidance from three obesity associations offers recommendations for specific obesity medications and spells out the need to reduce stigma. Will it help?
New research being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May), reveals distinct patterns of heart, metabolic, and inflammatory health risks between men ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results